Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2003 | 12-2002 | 12-2001 | 12-2000 | 12-1999 | |
| Sales | 12,582,500 | 11,077,500 | 11,542,500 | 10,862,200 | 10,002,900 |
| Cost of Goods | 2,675,100 | 2,176,500 | 2,160,200 | 2,055,700 | 2,098,000 |
| Gross Profit | 9,907,400 | 8,901,000 | 9,382,300 | 8,806,500 | 7,904,900 |
| Operating Expenses | 6,405,699 | 5,657,800 | 5,843,200 | 5,247,500 | 4,541,200 |
| Operating Income | 3,501,801 | 3,243,700 | 3,539,300 | 3,559,700 | 3,363,700 |
| Interest Expense | 61,000 | 79,700 | 191,700 | 182,300 | 183,800 |
| Other Income | -179,101 | 293,700 | 159,300 | 481,300 | 65,500 |
| Pre-tax Income | 3,261,700 | 3,457,700 | 3,506,900 | 3,858,700 | 3,245,400 |
| Income Tax | 700,900 | 749,800 | 726,900 | 800,900 | 698,700 |
| Net Income Continuous | 2,560,800 | 2,707,900 | 2,780,000 | 3,057,800 | 2,517,000 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | 174,300 |
| Net Income | $2,560,800 | $2,707,900 | $2,780,000 | $3,057,800 | $2,721,000 |
| EPS Basic Total Ops | 2.38 | 2.51 | 2.58 | 2.83 | 2.50 |
| EPS Basic Continuous Ops | 2.38 | 2.51 | 2.58 | 2.83 | 2.31 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | 0.16 |
| EPS Diluted Total Ops | 2.37 | 2.50 | 2.55 | 2.79 | 2.46 |
| EPS Diluted Continuous Ops | 2.37 | 2.50 | 2.55 | 2.79 | 2.28 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | 0.16 |
| EBITDA(a) | $4,050,301 | $3,736,700 | $3,994,200 | $3,995,500 | $3,803,400 |